<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<ibecs-document>
<record>
<header>
<identifier>ibc-88812</identifier>
<setSpec>0300-2896</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:title xml:lang="en">Lung Sarcoidosis Induced by TNF Antagonists in Rheumatoid Arthritis: A Case Presentation and a Literature Review</dc:title>
<dc:description xml:lang="en">Wereport on a 72 year-old woman with long-standing rheumatoid arthritis diagnosed as granulomatosisdue to pulmonary sarcoidosis after 49 months of treatment with etanercept. A clinical and radiologicalimprovement was seen after tumor necrosis factor (TNF) antagonist withdrawal plus a course of steroids.Currently, 27 cases of histological proven sarcoidosis with pulmonary involvement have been reportedin relation to anti-TNF therapy, with etanercept being more frequent in comparison with the anti-TNFmonoclonal antibodies infliximab and adalimumab. Potential pathogenic mechanisms of the paradoxicaleffect of anti-TNF treatment is discussed. It is important for clinicians to be aware of this potential anduncommon complication of biological therapy with TNF antagonists(AU)</dc:description>
<dc:creator>Gifre, Laia</dc:creator>
<dc:creator>Sanmartí, Raimon</dc:creator>
<dc:creator>Ruiz-Esquide, Virginia</dc:creator>
<dc:creator>Gómez-Puerta, José A</dc:creator>
<dc:creator>Xaubet, Antoni</dc:creator>
<dc:creator>Hernández, M. Victoria</dc:creator>
<dc:language>es</dc:language>
<dc:description xml:lang="es">Se presenta una paciente de 72 a&#152;nos con artritis reumatoide evolucionada que fue diagnosticada degranulomatosis pulmonar compatible con sarcoidosis tras 49 meses de tratamiento con etanercept. Elcuadro clínico y radiológico remitió al suspender el tratamiento contra el factor de necrosis tumoral (TNF)y con tratamiento corticoideo. Hasta la actualidad se han descrito 27 casos de sarcoidosis pulmonar,comprobados histológicamente, durante el tratamiento con antagonistas del TNF, siendo más frecuentecon etanercept que con los anticuerpos monoclonales anti-TNF infliximab y adalimumab. Se discuten losprobables mecanismos patogénicos de esta acción paradójica de los antagonistas del TNF. Es importantepara el clínico reconocer esta infrecuente complicación del tratamiento anti-TNF(AU)</dc:description>
<dc:source>Arch Bronconeumol;47(4): 208-212, abr. 2011. ilus, tab</dc:source>
<dc:identifier>ibc-88812</dc:identifier>
<dc:title xml:lang="es">Sarcoidosis pulmonar inducida por antagonistas del factor de necrosis tumoral en la artritis reumatoide: presentación de un caso y revisión de la literatura médica</dc:title>
<dc:subject>^d29611</dc:subject>
<dc:subject>^d1731^s22074</dc:subject>
<dc:subject>^d38737</dc:subject>
<dc:subject>^d21012</dc:subject>
<dc:subject>^d21034</dc:subject>
<dc:subject>^d23481^s22066</dc:subject>
<dc:subject>^d21030</dc:subject>
<dc:subject>^d23481^s22074</dc:subject>
<dc:subject>^d331</dc:subject>
<dc:subject>^d31059^s22032</dc:subject>
<dc:subject>^d31092^s22044</dc:subject>
<dc:subject>^d1178^s22016</dc:subject>
<dc:subject>^d31059^s22036</dc:subject>
<dc:subject>^d31059^s22012</dc:subject>
<dc:subject>^d920^s22073</dc:subject>
<dc:subject>^d1178^s22032</dc:subject>
<dc:subject>^d9062</dc:subject>
<dc:subject>^d29591^s22002</dc:subject>
<dc:subject>^d29591^s22021</dc:subject>
<dc:subject>^d1178^s22012</dc:subject>
<dc:subject>^d38737^s22002</dc:subject>
<dc:type>article</dc:type>
<dc:date>201104</dc:date>
</metadata>
</record>
</ibecs-document>
